MediciNova (MNOV) Q3 2026 earnings summary

Executive summary

• Development focus remains MN-166 (ibudilast) across neurological and other disorders, and MN-001 (tipelukast) for fibrotic and metabolic diseases.

• Q3 net loss narrowed YoY as R&D spending fell; cash was $29.3M at quarter-end, with management expecting funding through at least March 2028.

Financial highlights

• Q3 2026 revenue was $138,555 vs. $123,319; operating loss was $3.06M vs. $3.38M, and net loss was $2.84M vs. $3.05M.

• Q3 basic and diluted net loss per share was $0.06, unchanged YoY.

• 9M 2026 revenue was $783,978 vs. $257,918; operating loss was $8.44M vs. $10.19M, and net loss was $7.74M vs. $9.20M.

• 9M R&D and patent expense declined to $3.54M from $5.61M; G&A increased to $5.29M from $4.61M.

Outlook and guidance

• Management expects to maintain R&D costs through the remainder of 2026 as development programs progress, and expects operating losses for the next several years.

• Management believes working capital is sufficient to fund operations through at least March 2028, but cannot assure resources will fund all programs as planned.

• Development strategy includes grant-funded and investigator-sponsored trials, non-dilutive financing, and seeking strategic alliances for clinical development and commercialization.